



**sirona**  
biochem

# **Sirona Biochem Corp.**

December 2011

ADVANCING CHEMISTRY.  
ENHANCING HEALTH.™

**TSX-V: SBM**

# Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Sirona Biochem’s stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Sirona Biochem’s products, the ability to protect its intellectual property, and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

# Stabilized Carbohydrate Technology

- ▶ One major platform = multiple opportunities
- ▶ Experts in stable carbohydrate chemistry
- ▶ Unlock the potential to produce stable, new patented molecules

# An Answer to Carbohydrate Chemistry

## Typical Issues

- Unstable
- Toxic
- Unpredictable

## SBM Technology

- ▶ Stability
- ▶ Safety
- ▶ Bioavailability
- ▶ Efficacy

# Scientific Expertise

**Geraldine  
Deliencourt-  
Godefroy, PhD**  
Chief Scientific Officer

- Founder of TFChem
- “Red Medal Award” - French Senate, French Ministry of Research
- Francinov Prize of Research & Innovation
- Chemistry patents, top ranked publications

**Bertrand Plouvier,  
PhD**  
VP, Product  
Development

- Cardiome Pharma’s main Chemist developing Vernakalant, pending FDA approval
- Discovery of drug candidates for cardiac-arrhythmias & cough
- PhD University of Lille, Master in drug design Institut de Chimie Pharmaceutique de Lille, France
- Co-author of 12 publications and 6 patents

**TFChem Scientists**

- 4 PhD – Chemistry
- 1 PhD – Biology
- 4 Chemistry technicians

# We Fix Carbohydrates



## The Problem

- Unstable existing compounds
- Shelved compounds
- Expired/expiring patents



## The Repair Shop

- **Improve**
  - Stability
  - Efficacy
  - Bioavailability
  - Safety
  - Selectivity
- **Develop New Patented Compounds**
- **Go/No-Go – Cost Efficient**




## Commercially Valuable Products

- **Pharma Partners**
- **Cosmetic Companies**
- **Labs**

# Proprietary Chemistry Technology

## The Solution to Unstable Carbohydrate Molecules



# Targeting High Value Projects

Quick to Market

## THERAPEUTICS

### Diabetes/Obesity

- SGLT2 Inhibitor

### Cancer Vaccines

- Tn Antigen

### *Future Projects*

- Pain
- Inflammation

## COSMECEUTICALS

### Depigmenting Agent “Skin Whitener”

### “Anti-Aging” Cosmetic Agent

## BIOLOGICS


### DNA Inducer

- Recombinant protein production:
  - Insulin
  - Human growth hormone
  - Interferon (anti-viral)
  - Interleukin-2 (immune)

### Cell Preservation

- Stem/islet/blood cells
- Organ transplants

# SGLT2 Inhibitors – New Class of Diabetes Drugs



# Sirona SGLT2 Inhibitors for Diabetes

## *Improved Performance*

### Market Potential

- \$25B Market
- 4<sup>th</sup> largest
- 6<sup>th</sup> leading cause of death
- Unsatisfied market
- Need for new & different, non-insulin dependent therapies

### SBM Current Status

- ▶ Lead Compound with Favourable preclinical results
- ▶ Patents filed
- ▶ Continuing preclinical bioavailability and toxicity testing
- ▶ Advancing to pre-clinical proof of concept
- ▶ Develop “best in class” SGLT2 – Greater effectiveness overall

# Skin Lighteners: Overview

## *Improved Safety*

### Demand for Safer Products

- \$7.5B Market
- 5.5% Annual Growth Rate
- North America & Europe Emerging Markets
- Current Products Ineffective or Toxic
- Used in creams by major cosmetic companies

### SBM Current Status

- ▶ \$1.9M grant approval by French government
- ▶ Grant enough to fund to commercial-ready stage
- ▶ Patents filed
- ▶ Consortium group assembled to advance agent

# Sirona Management Team

## **Howard Verrico, MD**

Founder, President & CEO

- MD, Emergency Physician
- Venture capital & public markets experience

## **Geraldine Deliencourt-Godefroy, PhD**

Chief Scientific Officer

- Founder of TFChem
- “Red Medal Award”- French Senate, French Ministry of Research, Francinov Prize of Research & Innovation
- Chemistry patents, top ranked publications

## **Bertrand Plouvier, PhD**

VP, Product Development

- Discovery of drug candidates for cardiac-arrhythmias & cough
- Discovery & development of Vernakalant, pending FDA approval
- PhD University of Lille, Master in drug design Institut de Chimie Pharmaceutique de Lille, France
- Co-author of 12 publications and 6 patents

## **Christopher Hopton, CGA**

Chief Financial Officer

- Investment & finance consultant for private & public cos.
- Financial Planning, Policy, Business process improvement
- Central Resources Corp., Canadian Airlines, 360networks

# Sirona's Scientific Advisory Board

**Dr. Stuart Maddin, MD, FRCPC**

*Dermatology and Cosmetic Ingredient Development Expert*

**Dr. Michael Walker, PhD**

*Pharmacology/Pre-Clinical Drug Development Expert*

**Dr. Denis Richard, PhD**

*Pre-Clinical/Clinical Diabetes & Obesity Expert*

**M. Jacques Warcoin, LLB**

*IP, Trademark, Licensing/Partnering Expert*

**Dr. Bruce Verchere, PhD**

*Diabetes-Metabolic Disease Expert (Islet Cell Transplant)*

**Drs. B. Mario Pinto, Pierre Vogel, Eric LeClerc, Bernard Langlois**

*Carbohydrate and Fluorine Chemistry Experts Team*

# Minimize Risk, Cost & Time to Market

- ▶ Portfolio of new patented therapeutics
- ▶ Products with shorter time to market
- ▶ Create/target early partnerships and licensing opportunities



**sirona**  
biochem



[www.sironabiochem.com](http://www.sironabiochem.com)

TSX-V: SBM

ADVANCING CHEMISTRY.  
ENHANCING HEALTH.™

TSX-V: SBM